Tag Archives: Eli Lilly and Company

October, 2015

  • 8 October

    Lilly’s Breast Cancer Drug Receives FDA Breakthrough Therapy Designation

    INDIANAPOLIS, Oct. 8, 2015 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer. This designation is based on data from the …